Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.66 |
| ▸ | PGR | P06401 | 4/20 | 0.66 |
| ▸ | AR | P10275 | 3/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | ESR1 | P03372 | 1/20 | 0.66 |
| ▸ | SHBG | P04278 | 1/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | HRH2 | P25021 | 1/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.66 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.66 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6564737 | 1.00 | CYP3A4 (0.66) | CYP3A4PGRARNR3C1LMNA | |
| SCHEMBL6564735 | 1.00 | CYP3A4 (0.66) | CYP3A4PGRARNR3C1LMNA | |
| SCHEMBL11206531 | 0.90 | CYP3A4 (0.55) | CYP3A4PGRARNR3C1LMNA | |
| SCHEMBL17419461 | 0.89 | MEN1 (0.59) | CYP3A4PGRARNR3C1LMNA | |
| SCHEMBL6836064 | 0.85 | PGR (0.67) | CYP3A4PGRARNR3C1LMNA | |
| SCHEMBL11272818 | 0.85 | PGR (0.67) | CYP3A4PGRARNR3C1LMNA | |
| SCHEMBL6836061 | 0.85 | PGR (0.67) | CYP3A4PGRARNR3C1LMNA | |
| SCHEMBL6836062 | 0.85 | PGR (0.67) | CYP3A4PGRARNR3C1LMNA | |
| SCHEMBL6563217 | 0.83 | HIF1A (0.64) | CYP3A4PGRARNR3C1LMNA | |
| SCHEMBL6343098 | 0.83 | HIF1A (0.64) | CYP3A4PGRARNR3C1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828120-B2 | Preparation of 11 beta ,17 alpha ,21- trihydroxy-6 alpha -methylpregna-1,4-diene-3,20-dione 21-acetate; obtain chemical intermediates, incubate reaction mix and enzymes, recover product | PHARMACIA AND UPJOHN COMPANY | 2004-12-07 | — | — | US | disclosed |
| EP-1399463-A1 | PROCESS TO PREPARE 11$g(b),17$g(a),21-TRIHYDROXY-6$g(a)-METHYLPREGNA-1,4-DIENE-3,20-DIONE 21-ACETATE | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030044885-A1 | Process to prepare 11beta, 17alpha,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-acetate | CRIA, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002102826-A1 | PROCESS TO PREPARE 11β,17α,21-TRIHYDROXY-6α-METHYLPREGNA-1,4-DIENE-3,20-DIONE 21-ACETATE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
| EP-0941361-B1 | A METHOD FOR THE PREPARATION OF STEROID COMPOUNDS | DURAMED EUROP LTD (GB) | 2001-11-28 | — | — | EP | disclosed |
| EP-0941361-A1 | A METHOD FOR THE PREPARATION OF STEROID COMPOUNDS | Duramed Europe Limited (GB) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998020151-A9 | A METHOD FOR THE PREPARATION OF STEROID COMPOUNDS | DURAMED EUROP LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
| WO-1998020151-A1 | A METHOD FOR THE PREPARATION OF STEROID COMPOUNDS | DURAMED EUROPE LIMITED (GB) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044885-A1 | Process to prepare 11beta, 17alpha,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-acetate | CYP17A1, CYP51A1, HSD17B11 | CYP3A4 86/4885PGR 339/4885AR 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.